Journal ArticleOPEN ACCESS

Ibrutinib‐induced severe liver injury

  • Nandikolla A
  • Derman O
  • Nautsch D
  • et al.
Clinical Case Reports (2017) 5(6) 735-738
DOI: 10.1002/ccr3.881
N/ACitations
Citations of this article
23Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Ibrutinib, an inhibitor of the Bruton's tyrosine kinase of the B‐cell receptor pathway, is an effective therapeutic agent for B‐cell lymphomas. As these drugs are novel, long‐term or rare adverse events are not yet known. We report the first case of ibrutinib‐induced severe liver injury in a patient with relapsed/refractory CLL.

Cite

CITATION STYLE

APA

Nandikolla, A. G., Derman, O., Nautsch, D., Liu, Q., Massoumi, H., Venugopal, S., … Janakiram, M. (2017). Ibrutinib‐induced severe liver injury. Clinical Case Reports, 5(6), 735–738. https://doi.org/10.1002/ccr3.881

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free